Solazyme, Inc. (NASDAQ:SZYM) announced today the closing of its sale of 5,750,000 shares (the “Shares”) of its common stock, and $149.5 million aggregate principal amount of 5.00% Convertible Senior Subordinated Notes due 2019 (the “Notes” and together with the Shares, the “Securities”), in each case pursuant to separate public offerings of the Securities. The Securities include 750,000 Shares and $19.5 million aggregate principal amount of Notes sold pursuant to the exercise in full of options granted to the respective underwriters of the offerings.
Solazyme has received aggregate net proceeds from the sale of the Securities of approximately $202.8 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by Solazyme. Solazyme intends to use the net proceeds for capital expenditures, working capital and general corporate purposes.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.
About Solazyme, Inc.Solazyme, Inc. (SZYM) is a renewable oil and bioproducts company that transforms a growing range of abundant plant-based sugars into high-value triglyceride oils and other bioproducts. Headquartered in South San Francisco, Solazyme's renewable products can replace or enhance oils derived from the world's three existing sources - petroleum, plants and animal fats. Solazyme is commercializing its primary products as either tailored oils, powdered oils, and closely related products in the chemicals, fuels and food markets or as branded consumer products. Solazyme®, the Solazyme logo and other trademarks or service names are trademarks of Solazyme, Inc. Forward-Looking Statements This press release includes forward-looking statements regarding Solazyme's financing plans, including statements related to Solazyme's intended use of the net proceeds from the sale of the Securities. Such statements are subject to certain risks and uncertainties including, without limitation, risks related to market and other general economic conditions and the anticipated use of the net proceeds from the sale of the Securities. Solazyme's forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Solazyme's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Solazyme. As a result, you are cautioned not to rely on these forward-looking statements.